Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 332

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Efficacy and Safety of Adjusted-Dose Prasugrel Compared With Clopidogrel in Japanese Patients With Acute Coronary Syndrome: – The PRASFIT-ACS Study –

Open access
Saito, Shigeru, Isshiki, Takaaki, Kimura, Takeshi, Ogawa, Hisao, Yokoi, Hiroyoshi, Nanto, Shinsuke, Takayama, Morimasa, Kitagawa, Kazuo, Nishikawa, Masakatsu, Miyazaki, Shunichi, Nakamura, Masato · 2014 · Circulation Journal

Abstract

BACKGROUND: Prasugrel is an antiplatelet agent that shows more prompt, potent, and consistent platelet inhibition than clopidogrel. The objective of this study was to confirm the efficacy and safety of prasugrel at loading/maintenance doses of 20/3.75 mg. METHODS AND RESULTS: Japanese patients (n=1,363) with acute coronary syndrome undergoing percutaneous coronary intervention were randomized to either prasugrel (20/3.75 mg) or clopidogrel (300/75 mg), both in combination with aspirin (81-330 mg for the first dose and 81-100 mg/day thereafter), for 24-48 weeks. The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke. We compared the incidence of MACE between the 2 groups using point estimates. Safety outcomes included the incidence of bleeding events until 2 weeks after the last dose. The incidence of MACE at 24 weeks was 9.4% in the prasugrel group and 11.8% in the clopidogrel group (risk reduction 23%, hazard ratio 0.77, 95% confidence interval 0.56-1.07). The incidence of non-coronary artery bypass graft-related major bleeding was similar in both groups (1.9% vs. 2.2%). CONCLUSIONS: Prasugrel 20/3.75 mg was associated with a low incidence of ischemic events, similar to the results of TRITON-TIMI 38, and with a low risk of clinically serious bleeding in Japanese ACS patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1253/circj.cj-13-1482

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 332

Metadata

Authors
Saito, S., Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Nishikawa, M., Miyazaki, S., & Nakamura, M.
Venue
Circulation Journal
Published
2014
Volume
78
Issue
7
Pages
1684-1692
ISSN
  • 1346-9843 (ISSN-L)
  • 1347-4820
OpenAlex
W1923386888
Cited by
332
References
13
FWCI
15.79
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Adjusted-Dose Prasugrel Compared With Clopidogrel in Japanese Patients With Acute Coronary Syndrome: – The PRASFIT-ACS Study –. https://app.cochat.ai/papers/10.1253/circj.cj-13-1482
The paper
Saito, S., Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Nishikawa, M., Miyazaki, S., & Nakamura, M. (2014). Efficacy and Safety of Adjusted-Dose Prasugrel Compared With Clopidogrel in Japanese Patients With Acute Coronary Syndrome: – The PRASFIT-ACS Study –. Circulation Journal. https://doi.org/10.1253/circj.cj-13-1482

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.